Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 2059


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Delivery
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2059

License Grant
The Company has licensed eleven formulated branded oral controlled-release products; providing the therapeutic benefits of controlled-release drug delivery.  The royalty rate reflects the fact that these drugs were licensed before clinical trials had been completed and, as a result, significant development risks were shared by the various undisclosed licensees.

IPSCIO Record ID: 5407

License Grant
The Licensor has entered into agreement with the Licensee which is developing several potential products which are vaccine based.
Field of Use
The Licensee wishes to use a combination of liposomes or cochleates in conjunction with Sendai vital proteins and its HIV synthetic peptides to create an EradicAide HIV Vaccine.
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.

To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.

IPSCIO Record ID: 7086

License Grant
The Licensee received an exclusive worldwide License to develop and commercialize ten 505(b)(2) products (brandable pharmaceutical products that qualify for filing with the United States Food and Drug Administration) and ten generic products (generic bio-equivalents of branded 7 products which qualify for filing with the FDA pursuant to an Abbreviated New Drug Application) under the Licensor Technology within a three year period.
Field of Use
The Licensee is a pharmaceutical company focusing on the development of oral controlled-release drug formulations utilizing proprietary drug formulations and delivery technologies.  The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.